Alimera Sciences, Inc
ATLANTA, Jul 29, 2010 (GlobeNewswire via COMTEX News Network) --
Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a
biopharmaceutical company that specializes in the research, development and
commercialization of prescription ophthalmic pharmaceuticals, today announced
that it will release its second quarter 2010 financial results after the
market close on Thursday, August 12, 2010. An investor conference call will
follow on the same day at 4:30 p.m. ET.
The conference call will be hosted by Dan Myers, President and
Chief Executive Officer, and Rick Eiswirth, Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (U.S. and
Canada) or (253) 237-1165 (international). A live webcast will be available
on the Investor Relations section of the corporate website at http://www.alimerasciences.com.
A replay of the conference call will be available beginning
August 12, 2010 at 7:30 p.m. ET and ending on August 26, 2010 by dialing
(800) 642-1687 (U.S. and Canada) or (706) 645-9291 (international),
Conference ID Number: 87900429. A replay of the webcast will be available on
the corporate website for two weeks, through August 26, 2010.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a
biopharmaceutical company that specializes in the research, development and
commercialization of prescription ophthalmic pharmaceuticals. Presently the
Company is focused on diseases affecting the back of the eye, or retina. Its
advanced product candidate Iluvien(R) is an intravitreal insert containing
fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated
efficacy in the treatment of ocular disease. Iluvien(R) is in development for
the treatment of diabetic macular edema (DME), a disease of the retina that
affects individuals with diabetes and can lead to severe vision loss and
blindness.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Alimera Sciences, Inc.
CONTACT: ICR, LLC
for Alimera Sciences
Donald Ellis
925-253-1240
[email protected]